Business
Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma
Anti-BCMA AlloCAR T Cells Maintained Phenotype and Sustained Potent Anti-Tumor Responses After Scaled-Up ManufacturingALLO-715 Investigational New Drug
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"Anti-BCMA AlloCAR T Cells Maintained Phenotype and Sustained Potent Anti-Tumor Responses After Scaled-Up ManufacturingALLO-715 Investigational New Drug Application and Phase 1 Trial Initiation Expected in 2019SOUTH SAN FRANCISCO, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the publication of preclinical study results of ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), as a potential novel treatment for multiple myeloma and other BCMA-positive malignancies, in Molecular Therapy. Results of the study were previously presented at the 60thAmerican Society of Hematology (ASH) Annual Meeting & Exposition in December 2018.\"These preclinical findings validate advancing ALLO-715 produced via our proprietary manufacturing process to target BCMA, which is expressed in multiple myeloma,\" said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. \"We look forward to filing the company's second Investigational New Drug Application this year and initiating a Phase 1 clinical trial of ALLO-715 in relapsed or refractory multiple myeloma.\"In this study, healthy donor T cells were transduced with several candidate anti-BCMA CARs and modified using gene editing to improve CAR T cell persistence and reduce risk of graft-versus-host disease (GvHD). The safety profile of allogeneic BCMA CAR T cells was further enhanced by incorporating a CD20-based off-switch enabling effective CAR T elimination in the presence of rituximab. Allogeneic BCMA CAR T cells induced sustained antitumor responses in mice and maintained their phenotype and potency after scaled-up manufacturing.ALLO-715 utilizes the TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene holds the global development and commercial rights for this investigational candidate. This pre-clinical research was conducted in collaboration with both Cellectis and Pfizer Cancer Immunology Discovery.About Multiple MyelomaMultiple myeloma is a type of cancer that typically affects an elderly population and is a B-cell malignancy.i Characterized by abnormalities in plasma cells, which reproduce uncontrollably in the bone marrow of people with the dis...